Piramal Pharma (NSE:PPLPHARMA) Current Accrued Expense : ₹0 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Piramal Pharma Current Accrued Expense?

Piramal Pharma's Current Accrued Expense for the quarter that ended in Mar. 2024 was ₹0 Mil.

Piramal Pharma Current Accrued Expense Historical Data

The historical data trend for Piramal Pharma's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Piramal Pharma Current Accrued Expense Chart

Piramal Pharma Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

Current Accrued Expense

Piramal Pharma Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial							-	-	-	-	-

Piramal Pharma Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Piramal Pharma Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Piramal Pharma's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Piramal Pharma (NSE:PPLPHARMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Piramal Pharma Ltd (NSE:PPLPHARMA) » Definitions » Current Accrued Expense

Traded in Other Exchanges

543635:India

Address

Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai, MH, IND, 400070

Website

https://www.piramal.com

Piramal Pharma Ltd offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries. It includes integrated contract development and manufacturing organization business, complex hospital generics business, and India consumer healthcare business, selling over-the-counter products in India.

Piramal Pharma (NSE:PPLPHARMA) Headlines

No Headlines